Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
164 During the randomized drug withdrawal phase, 74% of patients in the placebo group experienced recurrence of pericarditis, whereas only 7% of patients in the Rilonacept group experienced recurrence
Ask for help if symptoms persist or worsen
The compound received marketing approval in China in June 2025 under the brand name Xinermei, making it the first domestically approved dual GLP-1/glucagon agonist anywhere in the world
:max_bytes(150000):strip_icc():focal(745x171:747x173)/post-malone-112425-1-6916474753bd47e8885a58f279c4a033.jpg)
[PubMed | ClinicalTrials.gov | DOI] Wadden TA, Chao AM, Engel S, et al
If you ever miss a dose, follow your doctors instructions or the guidance provided with the pen
US$ 21.72
US$ 23.72
US$ 21.01
US$ 29.47
US$ 27.40
US$ 25.29
